Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials and found it to be a suitable alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia.
Balugrastim, a new long-lasting recombinant granulocyte colony-stimulating factor, is an alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia. Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials involving breast cancer patients treated with doxorubicin and doxetaxel, and published their findings in Therapeutics and Clinical Risk Management.
Neutropenia and febrile neutropenia are 2 frequent complications of chemotherapy treatment and recombinant granulocyte colony-stimulating factors are used to preserve absolute neutrophils count throughout the duration of chemotherapy treatment.
Thus far there has been limited literature available on balugrastim. The researchers assessed the available studies and found that balugrastim did not cause any severe adverse events or compromise quality of life. The administration of balugrastim was found to be extremely safe, and it had a slight advantage over pegfilgrastim in shortening the mean time to absolute neutrophils count recovery.
However, since all the studies analyzed were performed in homogenous populations of breast cancer patients treated with docetaxel and doxorubicin, the authors recommend additional research involving different tumor types and chemotherapy combinations, as well as long-term studies to adequately evaluate the safety of balugrastim.
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Read More
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More